Founded in 2022, AlgenScribe is building an innovative, patented platform that integrates advanced molecular biology tools for gene editing. The company’s technology is currently under development and is supported by several French regional and national innovation programs and incubators. With the fresh capital, AlgenScribe intends to continue refining its platform and, by early 2026, transfer its tools toward ex vivo applications. The startup benefits from backing by entities such as the incubateur Provence Côte d’Azur, Région Sud, Eurobiomed, Medicen, the ANR, Bpifrance and YES Invest. Management has already outlined plans for another fund-raise targeted for late 2026 or early 2027 to accelerate commercialization. The latest financing totals €470,000, providing runway for ongoing R&D and proof-of-concept milestones.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025